Lanean...
Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells
The receptor tyrosine kinase inhibitor lapatinib, indicated to treat patients with HER2-positive breast cancer in combination with capecitabine, can cause severe hepatotoxicity. Lapatinib is further associated with mitochondrial toxicity and accumulation of reactive oxygen species. The effect of lap...
Gorde:
Egile Nagusiak: | , , , |
---|---|
Formatua: | Artigo |
Hizkuntza: | Inglês |
Argitaratua: |
Frontiers Media S.A.
2020-06-01
|
Saila: | Frontiers in Pharmacology |
Gaiak: | |
Sarrera elektronikoa: | https://www.frontiersin.org/article/10.3389/fphar.2020.00944/full |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|